INTRODUCTION AND OBJECTIVES: Disease recurrence after radical cystectomy (RC) generally occurs within 2 years and has a poor prognosis. Little is known about the small group of patients who experience a late recurrence (>3 years after RC) outside of the urinary tract. In this study, we report our institutional experience with late recurrences and describe the relationships between time to recurrence, management strategies, and survival.
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METHODS: The study cohort comprised 2,315 patients who underwent RC for urothelial carcinoma at our center between 2000-2014, of whom 617 had a recurrence of disease outside of the urinary tract (n[559 <[3 years after RC, 58 >3 years after RC). Median follow up for survivors was 2.6 years post-recurrence (IQR 0.95, 4.5) . We compared baseline characteristics and post-recurrence management between those with recurrence <[3 and >3 years after RC. We presented the Kaplan-Meier estimates of survival and used the log-rank test to compare survival between early and late-recurring patients.
RESULTS: Patients with late recurrences had significantly lower consensus T stage, frequency of nodal involvement, and prevalence of multiple recurrence sites (p<0.05). The average 1-year bladder cancer death rate from the time of recurrence declined from 66% to 50% to 33% for patients with recurrence times of 6 months, 2 years, and 5 years after RC, respectively. For patients who survived at least one year after recurrence, the estimated survival at 5 years after RC was 45% for late recurring patients and 21% for patients who had an early recurrence (p[0.03, Figure 1A ). Local consolidative therapy (metastasectomy or radiation) was more common in patients with late recurrence (19% vs. 3.6%, p<0.0001). In the subset of patients receiving local consolidative therapy, post-recurrence cancer-specific survival in late-recurring patients was significantly better than in earlyrecurring patients (p[0.02, Figure 1B) .
CONCLUSIONS: The prolonged lifespan of patients experiencing a late recurrence after RC can be leveraged to individualize management. There is strong rationale for investigating the role of metastasectomy in the management of late recurrences. METHODS: NSQIP was queried to identify all obese BC patients who underwent either RARC or ORC between 2005e2016. Patient demographics, medical comorbidities, American Society of Anesthesiologists (ASA) classification, operative time (OPTIME), length of stay (LOS) and 30-day postoperative complications were recorded. Each RARC patient as matched with 3 ORC patients using a propensity score (PS) approach. Relative risk (RR [95%CI]) of 30-day post-operative complications in RARC vs. ORC patients was calculated and adjusted for matched design.
RESULTS: 442 RARC patients were matched with 1326 ORC patients. In both groups, the most common age group was 65-74 years (37%) and most were males (75-78%), white (84%), current nonsmokers (82%) and ASA class III (64-65%). Hypertension (65-66%) and diabetes (25-27%) were the most prevalent comorbidities in both groups. Compared to ORC, RARC group showed shorter mean OPTIME (364.7 (SD[133.4) vs 387.8 (SD[129.7) minutes, p[0.001) and mean LOS (7.1 (SD[5.6) vs 10.6 (SD[ 6.6) days, p<0.001). The incidences of the most common complications among the two groups are illustrated in table 1. Compared to ORC, the relative risk of developing these complications in RARC group was lower (table 1): 30-day postoperative any complication (49%), any readmission (29%), blood transfusion (71%), sepsis (34%), return to operating room (49%), wound disruption (73%), organ space infection (pelvic collection), Superficial and deep wound infection (44%, 79% and 74% respectively).
CONCLUSIONS: RARC for obese BC patients is associated with shorter OPTIME, shorter LOS and lower risk of early postoperative complications compared to ORC.
